TLPH · Talphera, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt about the Company's ability to continue as a going concern. While management believes its plans to raise additional funds will alleviate the conditions that raise substantial doubt about the Company's ability to continue as a going concern, these plans are not entirely within the Company's control and cannot be assessed as being probable of occurring.”View the 10-Q filed Aug 12, 2026
Press releases and events scraped from the company's investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-08-12 |
Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from previous guidelines Updated market research indicates an estimated 200,000 annual U.S. |
| 2026-08-05 |
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conference call and |
| 2026-05-13 |
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET SAN MATEO, Calif., May 13, 2026 /PRNewswire/ -- Talphera, Inc. |
| 2026-05-07 |
Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2026 |
| 2026-03-25 |
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026
SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the acceptance of two abstracts for |
| 2026-03-23 |
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million All 12 clinical study sites now able to enroll patients to support an expected study completion in 2026 Cash and investments of $20.4 |
| 2026-03-18 |
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026
SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a virtual investor |
| 2026-03-02 |
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial
Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to host a virtual investor and analyst event on March 23 at 11:00 am ET featuring nephrologists, Dr. Blaithin McMahon and Dr. Joao Teixeira SAN MATEO, Calif., March 2, 2026 |
| 2025-11-12 |
Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million ; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late |
| 2025-11-05 |
Talphera to Host Third Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, November 12, 2025
SAN MATEO, Calif. , Nov. 5, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release third quarter 2025 |
| 2025-10-21 |
Talphera Announces the Appointment of Joe Todisco to Board of Directors
SAN MATEO, Calif. , Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco , the CEO |
| 2025-09-08 |
Talphera Announces Private Placement Financing of up to $29 Million Priced At-the Market
CorMedix is making a strategic investment in Talphera as the lead investor, supported by existing stockholders Nantahala, Rosalind and Rock Springs with several new institutional investors $17 million in proceeds at first closing with the potential to receive an additional $12 million across one |
Past events
Source: https://ir.talphera.com/